Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Health Affairs (Project Hope)
|
January 17, 2003
Benefits of osteopathic schools
Erwin A Blackstone
American Health & Drug Benefits
|
April 12, 2016
The Economics of Medicare Accountable Care Organizations
Erwin A Blackstone, Joseph P Fuhr
Journal of Health Care Finance
|
November 1, 2008
Specialty hospitals: the economics and policy issues they pose
Erwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare
|
May 19, 2012
Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety
Erwin A Blackstone, Joseph P Fuhr
American Health & Drug Benefits
|
July 4, 2014
The economics of biosimilars
Erwin A Blackstone, P Fuhr Joseph
Biotechnology Healthcare
|
April 6, 2012
Biopharmaceuticals: the economic equation
Erwin A Blackstone, Joseph P Fuhr
Journal of Health Law
|
August 28, 2003
Failed hospital mergers
Erwin A Blackstone, Joseph P Fuhr
Future Medicinal Chemistry
|
March 25, 2011
Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals
Erwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare
|
February 12, 2013
Generic biopharmaceutical drugs: an economic and policy analysis
Erwin A Blackstone, Joseph P Fuhr
Evaluation and Program Planning
|
May 24, 2017
A regional, market oriented governance for disaster management: A new planning approach
Erwin A Blackstone, Simon Hakim, Brian Meehan
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Health Affairs (Project Hope)
|
January 17, 2003
Benefits of osteopathic schools
Erwin A Blackstone
American Health & Drug Benefits
|
April 12, 2016
The Economics of Medicare Accountable Care Organizations
Erwin A Blackstone, Joseph P Fuhr
Journal of Health Care Finance
|
November 1, 2008
Specialty hospitals: the economics and policy issues they pose
Erwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare
|
May 19, 2012
Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety
Erwin A Blackstone, Joseph P Fuhr
American Health & Drug Benefits
|
July 4, 2014
The economics of biosimilars
Erwin A Blackstone, P Fuhr Joseph
Biotechnology Healthcare
|
April 6, 2012
Biopharmaceuticals: the economic equation
Erwin A Blackstone, Joseph P Fuhr
Journal of Health Law
|
August 28, 2003
Failed hospital mergers
Erwin A Blackstone, Joseph P Fuhr
Future Medicinal Chemistry
|
March 25, 2011
Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals
Erwin A Blackstone, Joseph P Fuhr
Biotechnology Healthcare
|
February 12, 2013
Generic biopharmaceutical drugs: an economic and policy analysis
Erwin A Blackstone, Joseph P Fuhr
Evaluation and Program Planning
|
May 24, 2017
A regional, market oriented governance for disaster management: A new planning approach
Erwin A Blackstone, Simon Hakim, Brian Meehan
Page
of 2